title: Chitosan iron(III) reduces phosphorus levels in alloxan diabetes-induced rats with signs of renal failure development.
abstract: This study evaluates the effect of complex cross-linked chitosan iron-(III) (CH-FeCL) polymer as phosphate binder in renal failure induced by alloxan (150 mg/kg, i.p.) in rats. The animals (male and female) were divided into four groups and received the treatment once a day for 15 days: (i) control group, which received a single injection of saline (3 ml/kg, i.p.) and normal diet; (ii) alloxan group, which received only a dose of alloxan and normal diet; (iii) phosphate (PO4) group, which received diet supplemented with phosphate 1.2%; and (iv) CH-FeCL group, which received diet supplemented with phosphate 1.2% + CH-FeCL 0.5% (0.054% Fe elemental). It was observed that the CH-FeCL treatment did not alter body-weight, relative weight of the organs and haematological parameters in the treated and control groups for both sexes. However, a decrease in serum phosphorus level of the CH-FeCL group was observed after 15 days, compared with the phosphate group in both sexes. The serum iron concentration of the CH-FeCL group did not differ from the control group in either sex. CH-FeCL polymer decreases intestinal phosphate absorption in rats with renal failure and is promising for the treatment of phosphate retention in patients with renal failure.
authors.affiliation: Chemical-Pharmaceutical Investigations Center (NIQFAR/CCS), University of Itajaí Valley (UNIVALI), Itajaí, Santa Catarina, Brazil.
authors.forename: Lisiane M R
authors.initials: LM
authors.lastname: Schöninger
authors.forename: Rafaela C
authors.initials: RC
authors.lastname: Dall'Oglio
authors.forename: Silvana
authors.initials: S
authors.lastname: Sandri
authors.forename: Clóvis A
authors.initials: CA
authors.lastname: Rodrigues
authors.forename: Cristiani
authors.initials: C
authors.lastname: Bürger
mesh_terms: D000496:Alloxan; D000818:Animals; D048271:Chitosan / Q000737:chemistry / Q000494:pharmacology*; D002712:Chlorides / Q000737:chemistry / Q000494:pharmacology*; D003432:Cross-Linking Reagents; D003921:Diabetes Mellitus, Experimental / Q000150:complications; D005260:Female; D005290:Ferric Compounds / Q000737:chemistry / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects; D007501:Iron; D008297:Male; D010710:Phosphates / Q000008:administration & dosage / Q000378:metabolism*; D010758:Phosphorus / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012737:Sex Factors
chemical_list: D002712:Chlorides; D003432:Cross-Linking Reagents; D005290:Ferric Compounds; D010710:Phosphates; D010758:Phosphorus; D000496:Alloxan; D048271:Chitosan; D007501:Iron; C024555:ferric chloride